Canaccord Genuity Expects Pending FDA Action to Create Catalyst for MAP Pharmaceuticals (MAPP)
Tweet Send to a Friend
Canaccord Genuity reiterated a Buy on MAP Pharmaceuticals (NASDAQ: MAPP) with a price target of $23.00.
Analyst Randall Stanicky ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst Randall Stanicky ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
